These cells not only could provide direct anti-tumor activity through their CAR but could also target heterogeneous tumors with a single-input receptor, which can be achieved by using TCRs of TIL-Ts that recognize a broad range of neoantigen epitopes free from MHC restriction. This evidence concerns the gene HLA-C and neoplasm.